UCB to Acquire Ra Pharma to Improve Therapies for Patients with Myasthenia Gravis and Other Rare Diseases

UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of Seizure Cluster in Epilepsy in the US


  • UCB acquires Ra Pharma in all stock and cash transaction making total deal value $2.1B. Ra Pharma to receive $48 in cash for each share, representing a premium of 93% based on the 30-day volume weighted average closing stock price of Ra Pharma prior to signing with its expected closure in Q1 2020
  • The focus of the acquisition is to strengthen its footprints in neurology and immunology franchises with the addition of Ra Pharma’s late and early stage candidates and including Ra Pharma’s Zilucoplan, a P-III candidate for the treatment of Myasthenia Gravis. Additionally, UCB will get access to Ra Pharma’s ExtremeDiversity technology based on mRNA allowing the production of synthetic macrocyclic peptides
  • Zilucoplan (qd, self-administered, SC) is macrocyclic peptide binds to complement C5 with sub-nanomolar affinity and allosterically inhibiting its cleavage into C5a and C5b, currently evaluated in P-III in gMG with expected results in H1’21 and in P-II study in IMNM

Click here to­ read full press release/ article | Ref: PRNewsWire| Image: Twitter